Literature DB >> 28364177

Magnetic resonance imaging for characterizing myocardial diseases.

Maythem Saeed1, Hui Liu2, Chang-Hong Liang2, Mark W Wilson3.   

Abstract

The National Institute of Health defined cardiomyopathy as diseases of the heart muscle. These myocardial diseases have different etiology, structure and treatment. This review highlights the key imaging features of different myocardial diseases. It provides information on myocardial structure/orientation, perfusion, function and viability in diseases related to cardiomyopathy. The standard cardiac magnetic resonance imaging (MRI) sequences can reveal insight on left ventricular (LV) mass, volumes and regional contractile function in all types of cardiomyopathy diseases. Contrast enhanced MRI sequences allow visualization of different infarct patterns and sizes. Enhancement of myocardial inflammation and infarct (location, transmurality and pattern) on contrast enhanced MRI have been used to highlight the key differences in myocardial diseases, predict recovery of function and healing. The common feature in many forms of cardiomyopathy is the presence of diffuse-fibrosis. Currently, imaging sequences generating the most interest in cardiomyopathy include myocardial strain analysis, tissue mapping (T1, T2, T2*) and extracellular volume (ECV) estimation techniques. MRI sequences have the potential to decode the etiology by showing various patterns of infarct and diffuse fibrosis in myocarditis, amyloidosis, sarcoidosis, hypertrophic cardiomyopathy due to aortic stenosis, restrictive cardiomyopathy, arrythmogenic right ventricular dysplasia and hypertension. Integrated PET/MRI system may add in the future more information for the diagnosis and progression of cardiomyopathy diseases. With the promise of high spatial/temporal resolution and 3D coverage, MRI will be an indispensible tool in diagnosis and monitoring the benefits of new therapies designed to treat myocardial diseases.

Entities:  

Keywords:  Cardiomyopathy; Heart muscles; Magnetic resonance imaging

Mesh:

Year:  2017        PMID: 28364177     DOI: 10.1007/s10554-017-1127-x

Source DB:  PubMed          Journal:  Int J Cardiovasc Imaging        ISSN: 1569-5794            Impact factor:   2.357


  144 in total

1.  Role of T2* magnetic resonance in monitoring iron chelation therapy.

Authors:  John-Paul Carpenter; Dudley J Pennell
Journal:  Acta Haematol       Date:  2009-11-10       Impact factor: 2.195

2.  Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease.

Authors:  C G Brilla; R C Funck; H Rupp
Journal:  Circulation       Date:  2000-09-19       Impact factor: 29.690

Review 3.  New directions in the assessment and treatment of hypertensive heart disease.

Authors:  Arantxa González; Begoña López; Javier Díez
Journal:  Curr Opin Nephrol Hypertens       Date:  2005-09       Impact factor: 2.894

4.  Cardiovascular magnetic resonance in cardiac amyloidosis.

Authors:  Alicia Maria Maceira; Jayshree Joshi; Sanjay Kumar Prasad; James Charles Moon; Enrica Perugini; Idris Harding; Mary Noelle Sheppard; Philip Alexander Poole-Wilson; Philip Nigel Hawkins; Dudley John Pennell
Journal:  Circulation       Date:  2005-01-03       Impact factor: 29.690

5.  Magnetic resonance characterization of the peri-infarction zone of reperfused myocardial infarction with necrosis-specific and extracellular nonspecific contrast media.

Authors:  M Saeed; G Lund; M F Wendland; J Bremerich; H Weinmann; C B Higgins
Journal:  Circulation       Date:  2001-02-13       Impact factor: 29.690

6.  Cardiac Fibrosis in Aortic Stenosis and Hypertensive Heart Disease Assessed by Magnetic Resonance T1 Mapping.

Authors:  Florian von Knobelsdorff-Brenkenhoff; Anna-Katharina Mueller; Marcel Prothmann; Pierre Hennig; Matthias A Dieringer; Luisa Schmacht; Andreas Greiser; Jeanette Schulz-Menger
Journal:  J Heart Valve Dis       Date:  2016-09

7.  Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy.

Authors:  Raymond H Chan; Barry J Maron; Iacopo Olivotto; Michael J Pencina; Gabriele Egidy Assenza; Tammy Haas; John R Lesser; Christiane Gruner; Andrew M Crean; Harry Rakowski; James E Udelson; Ethan Rowin; Massimo Lombardi; Franco Cecchi; Benedetta Tomberli; Paolo Spirito; Francesco Formisano; Elena Biagini; Claudio Rapezzi; Carlo Nicola De Cecco; Camillo Autore; E Francis Cook; Susie N Hong; C Michael Gibson; Warren J Manning; Evan Appelbaum; Martin S Maron
Journal:  Circulation       Date:  2014-08-05       Impact factor: 29.690

8.  Myocardial fibrosis severity on cardiac magnetic resonance imaging predicts sustained arrhythmic events in hypertrophic cardiomyopathy.

Authors:  Christian Prinz; Maria Schwarz; Ivan Ilic; Kai Thorsten Laser; Roman Lehmann; Eva-Maria Prinz; Thomas Bitter; Jürgen Vogt; Frank van Buuren; Nikola Bogunovic; Dieter Horstkotte; Lothar Faber
Journal:  Can J Cardiol       Date:  2012-06-30       Impact factor: 5.223

9.  Diffuse myocardial fibrosis evaluation using cardiac magnetic resonance T1 mapping: sample size considerations for clinical trials.

Authors:  Songtao Liu; Jing Han; Marcelo S Nacif; Jacquin Jones; Nadine Kawel; Peter Kellman; Christopher T Sibley; David A Bluemke
Journal:  J Cardiovasc Magn Reson       Date:  2012-12-28       Impact factor: 5.364

10.  Reproducibility of in-vivo diffusion tensor cardiovascular magnetic resonance in hypertrophic cardiomyopathy.

Authors:  Laura-Ann McGill; Tevfik F Ismail; Sonia Nielles-Vallespin; Pedro Ferreira; Andrew D Scott; Michael Roughton; Philip J Kilner; S Yen Ho; Karen P McCarthy; Peter D Gatehouse; Ranil de Silva; Peter Speier; Thorsten Feiweier; Choukkri Mekkaoui; David E Sosnovik; Sanjay K Prasad; David N Firmin; Dudley J Pennell
Journal:  J Cardiovasc Magn Reson       Date:  2012-12-24       Impact factor: 5.364

View more
  9 in total

Review 1.  The MOGE(S) classification for cardiomyopathies: current status and future outlook.

Authors:  Julian G Westphal; Angelos G Rigopoulos; Constantinos Bakogiannis; Sarah E Ludwig; Sophie Mavrogeni; Boris Bigalke; Torsten Doenst; Matthias Pauschinger; Carsten Tschöpe; P Christian Schulze; Michel Noutsias
Journal:  Heart Fail Rev       Date:  2017-11       Impact factor: 4.214

2.  An integrated multi-objective whale optimized support vector machine and local texture feature model for severity prediction in subjects with cardiovascular disorder.

Authors:  M Muthulakshmi; G Kavitha
Journal:  Int J Comput Assist Radiol Surg       Date:  2020-03-09       Impact factor: 2.924

3.  Cardiac Magnetic Resonance for Lesion Assessment in the Electrophysiology Laboratory.

Authors:  Timothy M Markman; Saman Nazarian
Journal:  Circ Arrhythm Electrophysiol       Date:  2017-11

4.  Current use of cardiac magnetic resonance in tertiary referral centres for the diagnosis of cardiomyopathy: the ESC EORP Cardiomyopathy/Myocarditis Registry.

Authors:  Katarzyna Mizia-Stec; Philippe Charron; Juan Ramon Gimeno Blanes; Perry Elliott; Juan Pablo Kaski; Aldo P Maggioni; Luigi Tavazzi; Michał Tendera; Stephan B Felix; Fernando Dominguez; Natalia Ojrzynska; Maria-Angela Losi; Giuseppe Limongelli; Roberto Barriales-Villa; Petar M Seferovic; Elena Biagini; Maciej Wybraniec; Cecile Laroche; Alida L P Caforio
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2021-06-22       Impact factor: 6.875

Review 5.  Chinese society of cardiology expert consensus statement on the diagnosis and treatment of adult fulminant myocarditis.

Authors:  Daowen Wang; Sheng Li; Jiangang Jiang; Jiangtao Yan; Chunxia Zhao; Yan Wang; Yexin Ma; Hesong Zeng; Xiaomei Guo; Hong Wang; Jiarong Tang; Houjuan Zuo; Li Lin; Guanglin Cui
Journal:  Sci China Life Sci       Date:  2018-12-03       Impact factor: 6.038

6.  Association of smoking and physical inactivity with MRI derived changes in cardiac function and structure in cardiovascular healthy subjects.

Authors:  Anina Schafnitzel; Roberto Lorbeer; Christian Bayerl; Hannah Patscheider; Sigrid D Auweter; Christa Meisinger; Margit Heier; Birgit Ertl-Wagner; Maximilian Reiser; Annette Peters; Fabian Bamberg; Holger Hetterich
Journal:  Sci Rep       Date:  2019-12-09       Impact factor: 4.379

7.  Free-breathing gradient recalled echo-based CMR in a swine heart failure model.

Authors:  Craig C Morris; Jacob Ref; Satya Acharya; Kevin J Johnson; Scott Squire; Tuschar Acharya; Tyler Dennis; Sherry Daugherty; Alice McArthur; Ikeotunye Royal Chinyere; Jen Watson Koevary; Joshua M Hare; Jordan J Lancaster; Steven Goldman; Ryan Avery
Journal:  Sci Rep       Date:  2022-03-08       Impact factor: 4.379

8.  Cardiac MRI Assessment of Mouse Myocardial Infarction and Regeneration.

Authors:  Yijen L Wu
Journal:  Methods Mol Biol       Date:  2021

9.  Qishen granules exerts cardioprotective effects on rats with heart failure via regulating fatty acid and glucose metabolism.

Authors:  Kuo Gao; Jian Zhang; Pengrong Gao; Qiyan Wang; Ying Liu; Junjie Liu; Yili Zhang; Yan Li; Hong Chang; Ping Ren; Jinmin Liu; Yong Wang; Wei Wang
Journal:  Chin Med       Date:  2020-03-04       Impact factor: 5.455

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.